Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
J ANTIINFECTIVES FOR SYSTEMIC USE
J05 ANTIVIRALS FOR SYSTEMIC USE
J05A DIRECT ACTING ANTIVIRALS
J05AJ Integrase inhibitors
J05AJ04 Cabotegravir
D10549 Cabotegravir sodium (JAN/USAN) <JP/US>
USP drug classification [BR:br08302]
Antivirals
Anti-HIV Agents, Integrase Inhibitors (INSTI)
Cabotegravir
D10549 Cabotegravir sodium (JAN/USAN)
Therapeutic category of drugs in Japan [BR:br08301]
6 Agents against pathologic organisms and parasites
62 Chemotherapeutics
625 Antivirals
6250 Antivirals
D10549 Cabotegravir sodium (JAN/USAN)
Drug groups [BR:br08330]
Antiviral
DG03107 Anti-HIV agent
DG03135 HIV integrase inhibitor
DG01628 Cabotegravir
D10549 Cabotegravir sodium
Metabolizing enzyme substrate
DG02924 UGT substrate
DG03183 UGT1A1 substrate
DG01628 Cabotegravir
D10549 Cabotegravir sodium
DG03188 UGT1A9 substrate
DG01628 Cabotegravir
D10549 Cabotegravir sodium
Drug classes [BR:br08332]
Antiviral
DG03107 Anti-HIV agent
D10549 Cabotegravir sodium
Antimicrobials [BR:br08307]
Antivirals
Genome replication inhibitor
HIV integrase inhibitor
D10549 Cabotegravir sodium (JAN/USAN) <JP/US>
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D10549
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D10549
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D10549
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D10549
Drug groups [BR:br08330]
Antiviral
DG03107 Anti-HIV agent
DG03135 HIV integrase inhibitor
DG01628 Cabotegravir
Metabolizing enzyme substrate
DG02924 UGT substrate
DG03183 UGT1A1 substrate
DG01628 Cabotegravir
DG03188 UGT1A9 substrate
DG01628 Cabotegravir